CTLA4 and neoplasm: To corroborate this result, we treated male C57BL/6 mice bearing orthotopic pancreatic tumors formed by the male KPC line HY24409 with dual ICB drugs (anti-CTLA-4 and anti-PD-l antibodies), finding no significant effect on tumor size or weight (Fig. 6a–d).